尼尔塞维马布治疗RSV支气管炎在儿科急诊室的治疗方法
Lea Lenglart1,2, Corinne Levy3,4,5,6, Romain Basmaci2,6,7
1Pediatric Emergency Department, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
JAMA network open
|October 30, 2025
概括
尼尔西维玛能有效地预防婴儿呼吸道综合体病毒 (RSV) 支气管炎,在使用的前两年表现出高效和可比效. 尽管出现了RSV-B耐药菌株,但持续监测至关重要.
科学领域:
- 儿童传染病 儿童传染病
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 呼吸道综合体病毒 (RSV) 支气管炎是儿童住院的主要原因之一.
- 尼尔塞维马布是一种单克隆抗体,用于预防RSV下呼吸道感染.
- 出现RSV-B耐药菌株需要持续评估nirsevimab的有效性.
研究的目的:
- 在法国实施的第一年和第二年,比较nirsevimab在预防RSV支气管炎的有效性.
- 评估RSV-B耐药菌株对nirsevimab临床疗效的影响.
主要方法:
- 一个多中心检测负的病例控制研究,涉及636名1岁以下的婴儿.
- 在两个RSV季节 (2023-2024年和2024-2025年) 中从儿科急诊室收集的数据.
- 用于计算nirsevimab有效性的多变量逻辑回归,根据相关共变量进行调整.
主要成果:
- 尼尔塞维马布的有效性在两个季节都很高:第一个季节为83.2% (95% CI,68.0%-91.4%),第二个季节为89.3% (95% CI,77.8%-95.1%).
- 在两个季节之间没有观察到有效性的统计学上显著差异 (P = .97).
- 小组和灵敏度分析证实了一致的发现.
结论:
- 在儿科急诊室,nirsevimab在抗RSV支气管炎方面表现出持续的高效.
- 到目前为止,目前的RSV-B耐药菌株并没有显著影响nirsevimab的临床有效性.
- 密切监测RSV流行病学和nirsevimab使用对于长期公共卫生战略至关重要.
更多相关视频
相关概念视频
Acute Respiratory Failure-IV
486
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
486
Pneumonia IV: Management
713
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
713
Acute Respiratory Failure-V
407
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
407
Acute Respiratory Failure-II
974
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
974
Acute Respiratory Failure-I
779
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
779
Acute Respiratory Failure-III
714
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
714


